Introduction

Epilepsy is the most frequent neurological pathology in children, and in some cases it has no adequate control with drug treatments. The improvement of epilepsy control observed during starvation periods triggered the development of a diet that simulates its alterations, allowing its use to treat difficult to control epileptic patients. Many researchers have demonstrated the efficacy of the ketogenic diet (KD) on controlling epileptic children. The mechanisms involved still remain unknown, though.

Objective

Assess clinical and laboratorial aspects of difficult to control epileptic children submitted to KD for a period of 18 to 24 months.

Material and methods

20 patients (10 boys and 10 girls) with median age of 6 years and 2 months were assessed three times: assessment 1 – inpatient service to start the diet; assessment 2 - 6 to 12 months and assessment 3 - 18 to 24 months after beginning the treatment. Weight and height measurements, and serum lipids and triacylglycerol dosages were assessed. A vitamin and mineral supplementation was prescribed. The ANOVA statistical test was used to compare the analyzed parameters.

Results

Clinical and neurological improvements were observed in all patients. Significant decrease occurred for the medium values for weight/age (W/A) and height/age (H/A) Z scores (p < 0.05), which didn’t occur with the BMI/age. Significant increase on the medium values for the serum total cholesterol and LDL-cholesterol (p < 0.05) had also been observed. The medium values for serum triacylglycerol had decreased, but it was not statistically significant (table I).

Discussion

KD can provide a better control for epileptic children. Considering all the nutritional restrictions involved, it is possible that alterations on growth and nutritional status may occur. The decrease on the W/A and H/A outcomes was probably consequent to the low caloric amount offered by the KD. The stability of the BMI/A shows a proportional growth stop (table 1). The higher amount of saturated fats ingested during the study caused an increase on serum lipids. The individual ability to metabolize fats contributed to normalize them (or not). The serum lipids dosage evidenced a significant increase in the medium values of total cholesterol, consequent to an increase of LDL-cholesterol.

Table I

<table>
<thead>
<tr>
<th></th>
<th>I</th>
<th>II</th>
<th>III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z BMI/A</td>
<td>-0.51 ± 1.7</td>
<td>-0.9 ± 1.2</td>
<td>-0.7 ± 1.6</td>
</tr>
<tr>
<td>Z W/A*</td>
<td>-0.41 ± 1.9</td>
<td>-0.95 ± 1.5</td>
<td>-1.2 ± 2.0</td>
</tr>
<tr>
<td>Z H/A*</td>
<td>-0.41 ± 1.5</td>
<td>-0.6 ± 1.4</td>
<td>-1.05 ± 1.3</td>
</tr>
<tr>
<td>Total Cholesterol</td>
<td>177.7 ± 35.1</td>
<td>203 ± 46.2</td>
<td>213.4 ± 43.7</td>
</tr>
<tr>
<td>Triacylglycerol</td>
<td>107.6 ± 54.9</td>
<td>94.8 ± 47.8</td>
<td>85.8 ± 28.8</td>
</tr>
<tr>
<td>LDL-cholesterol</td>
<td>123 ± 26.2</td>
<td>135.6 ± 48.0</td>
<td>151.7 ± 45.7</td>
</tr>
</tbody>
</table>

* p<0.05.
Conclusions

The growth velocity reduction observed in these patients, as well as the increase on the concentrations of serum lipids, indicate that the use of KD for longer periods should be discussed with rigorous criteria. Despite the clinical benefit, evidenced by the neurological improvement, there’s the need of follow-up, even after stopping the diet. The catch-up of growth must be assured to guarantee the nutritional safety of the diet.

References